TYR

Chr 11ADAR

tyrosinase

Also known as: ATN, CMM8, OCA1, OCA1A, OCAIA, SHEP3

The enzyme encoded by this gene catalyzes the first 2 steps, and at least 1 subsequent step, in the conversion of tyrosine to melanin. The enzyme has both tyrosine hydroxylase and dopa oxidase catalytic activities, and requires copper for function. Mutations in this gene result in oculocutaneous albinism, and nonpathologic polymorphisms result in skin pigmentation variation. The human genome contains a pseudogene similar to the 3' half of this gene. [provided by RefSeq, Oct 2008]

Primary Disease Associations & Inheritance

[Skin/hair/eye pigmentation 3, blue/green eyes]MIM #601800
AD
[Skin/hair/eye pigmentation 3, light/dark/freckling skin]MIM #601800
AD
{Melanoma, cutaneous malignant, susceptibility to, 8}MIM #601800
AD
Albinism, oculocutaneous, type IAMIM #203100
AR
Albinism, oculocutaneous, type IBMIM #606952
AR
584
ClinVar variants
210
Pathogenic / LP
0.00
pLI score
12
Active trials
Clinical SummaryTYR
🧬
Gene-Disease Validity (ClinGen)
oculocutaneous albinism type 1 · ARDefinitive

Definitive — sufficient evidence for diagnostic panels

Population Constraint (gnomAD)
Low constraint (pLI 0.00) — loss-of-function variants are relatively tolerated in the population.
📋
ClinVar Variants
210 Pathogenic / Likely Pathogenic· 140 VUS of 584 total submissions
💊
Clinical Trials
12 active or recruiting trials — potential therapeutic options may be available

Population Genetics & Constraint

gnomAD v4 — loss-of-function & missense intolerance

Tolerant — LoF & missense variants common in population
LoF Constraint?LOEUF (Loss-of-function Observed/Expected Upper bound Fraction) is the upper bound of the 90% CI for LoF OE — the preferred gnomAD v4 metric. Lower = more intolerant to LoF. LOEUF < 0.35 = highly constrained.
1.96LOEUF
pLI 0.000
Z-score -3.29
OE 1.77 (1.331.96)
Tolerant

Highly tolerant — LoF variants common in population

Missense Constraint?Missense Z-score: standard deviations fewer missense variants observed vs. expected. Z > 3.09 (p < 0.001) = gene does not tolerate missense variation. OE missense < 0.6 is also considered constrained.
-1.95Z-score
OE missense 1.32 (1.221.44)
379 obs / 286.1 exp
Tolerant

Tolerant to missense variation

Observed / Expected Ratios?Shaded band = 90% confidence interval. Vertical tick = point estimate. Grey threshold line = gnomAD constraint cutoff for that variant class.
LoF OE?Ratio of observed to expected LoF variants. Upper CI bound (LOEUF) ≤ 0.35 = strong LoF constraint signal.1.77 (1.331.96)
00.351.4
Missense OE?Ratio of observed to expected missense variants. OE ≤ 0.6 = fewer missense variants than expected by chance.1.32 (1.221.44)
00.61.4
Synonymous OE?Control metric — synonymous variants are largely neutral and expected near OE = 1.0. Significant deviation may indicate annotation issues.1.30
01.21.6
LoF obs/exp: 38 / 21.5Missense obs/exp: 379 / 286.1Syn Z: -2.41

ClinVar Variant Classifications

584 submitted variants in ClinVar

Classification Summary

Pathogenic98
Likely Pathogenic112
VUS140
Likely Benign184
Benign12
Conflicting38
98
Pathogenic
112
Likely Pathogenic
140
VUS
184
Likely Benign
12
Benign
38
Conflicting

Curated Variants Distribution

Classified variants from ClinVar · 5 ACMG categories

ClassificationLoFMissense + InframeNon-codingSynonymousTotal
Pathogenic
35
23
40
0
98
Likely Pathogenic
21
68
23
0
112
VUS
1
119
16
4
140
Likely Benign
0
2
46
136
184
Benign
0
1
10
1
12
Conflicting
38
Total57213135141584

LoF = frameshift, stop gained/lost, canonical splice · Counts from ClinVar esearch · Updated hourly

View in ClinVar →

Protein Context — Lollipop Plot

TYR · protein map & ClinVar variants

Showing all ClinVar variants across the protein. Search a specific variant to highlight its position.

Gene2Phenotype Curations

TYR-related oculocutaneous albinism

definitive
ARLoss Of FunctionAbsent Gene Product
Dev. DisordersEyeSkin
G2P ↗

Gene2Phenotype curations · DECIPHER consortium patient cohort (public variants) · deciphergenomics.org

OMIM — Genotype-Phenotype Relationships

1 OMIM entry

TYROSINASE; TYR
MIM #606933 · *

[Skin/hair/eye pigmentation 3, blue/green eyes]

MIM #601800

Molecular basis of disorder known

Autosomal dominant

[Skin/hair/eye pigmentation 3, light/dark/freckling skin]

MIM #601800

Molecular basis of disorder known

Autosomal dominant

{Melanoma, cutaneous malignant, susceptibility to, 8}

MIM #601800

Molecular basis of disorder known

Autosomal dominant

Albinism, oculocutaneous, type IA

MIM #203100

Molecular basis of disorder known

Autosomal recessive

Albinism, oculocutaneous, type IB

MIM #606952

Molecular basis of disorder known

Autosomal recessive
📖
GeneReview available — TYR
Authoritative clinical overview · NCBI Bookshelf · Recommended first read
Open GeneReview ↗
Clinical Literature
Landmark / reviewRecent case evidence
Key Publications
Landmark & review papers · by relevance
PubMed
Top 10 resultsSearch PubMed ↗

Clinical Trials

Active and recruiting trials from ClinicalTrials.gov

Locally Advanced CholangiocarcinomaIntrahepatic CholangiocarcinomaSolid Tumor

Safety and Anti-Tumor Activity of TYRA-200 in Advanced Cholangiocarcinoma With Activating FGFR2 Gene Alterations

RECRUITING
NCT06160752Phase PHASE1Tyra Biosciences, IncStarted 2023-11-22
Phase 1 Part A - dose escalation TYRA-200 taken once daily by mouth in 28-day cyclesPhase 1 Part B - dose expansion TYRA-200 taken once daily by mouth in 28-day cycles
Non-small Cell Lung CancerALK Gene Rearrangement Positive

Analysis of Biological Characteristics of Advanced ALK-rearranged NSCLC

RECRUITING
NCT05122806Phase NAGroupe Francais De Pneumo-CancerologieStarted 2021-09-22
RNAseq
Chronic Myeloid Leukemia, Chronic PhaseWithdrawal;Drug

Efficacy and Safety of TKIs' Withdrawal After a Two-step Dose Reduction in Patients with Chronic Myeloid Leukemia

ACTIVE NOT RECRUITING
NCT04147533Phase PHASE2Masaryk UniversityStarted 2020-06-16
Imatinib withdrawalDasatinibNilotinib
MASLD - Metabolic Dysfunction-Associated Steatotic Liver DiseaseMetabolic Dysfunction-Associated Steatohepatitis (MASH)

Assessment of Gut Microbiota-Derived Amino Acid Metabolite Production in Patients With MASLD

NOT YET RECRUITING
NCT07313007Phase NAHospices Civils de LyonStarted 2026-01-01
stool sampling, dietary assessment, and collection of blood and urine samples
Carcinoma, Renal Cell

Study to Evaluate the Safety and Efficacy of Bicalutamide in Combination with Sunitinib in Patients with TKIs-resistant RCC

RECRUITING
NCT06222593Phase PHASE1, PHASE2State University of New York at BuffaloStarted 2024-10-01
Bicalutamide in combination with Sunitinib
EGFR Tyrosine Kinase Inhibitors Plus Cyclin-dependent Kinase 4/6 Inhibitor

A Study of Almonertinib Combined With Palbociclib in Patients With Advanced Solid Tumors Harboring KRAS Mutations

RECRUITING
NCT06947811Phase PHASE1, PHASE2Sun Yat-sen UniversityStarted 2025-06-09
AlmonertinibPalbociclib
Colitis Ulcerative

A Study to Investigate the Efficacy and Safety of Dupilumab Therapy Compared With Placebo in Participants Aged ≥18 Years With Moderately to Severely Active Ulcerative Colitis With an Eosinophilic Phenotype (LIBERTY-UC SUCCEED (Study in UC for Clinical Efficacy Evaluation of Dupilumab))

ACTIVE NOT RECRUITING
NCT05731128Phase PHASE2SanofiStarted 2023-01-12
DupilumabPlacebo
Advanced Lung Non-Small Cell CarcinomaMetastatic Lung Non-Small Cell CarcinomaStage IV Lung Cancer AJCC v8

MRX-2843 and Osimertinib for the Treatment of Advanced EGFR Mutant Non-small Cell Lung Cancer

RECRUITING
NCT04762199Phase PHASE1Emory UniversityStarted 2021-02-24
Flt3/MerTK Inhibitor MRX-2843Osimertinib
Advanced LymphomaAdvanced Malignant Solid NeoplasmBladder Carcinoma

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

ACTIVE NOT RECRUITING
NCT02465060Phase PHASE2National Cancer Institute (NCI)Started 2015-08-17
AdavosertibAfatinibAfatinib Dimaleate
Non-small Cell Lung CancerEGFR Gene MutationEGFR-TKI Resistant Mutation

Nintedanib Plus EGFR TKI In EGFR-mutated Non-small Cell Lung Cancer Patients

RECRUITING
NCT06071013Phase PHASE1, PHASE2China Medical University HospitalStarted 2024-02-23
Nintedanib, gefitinib, erlotinib, afatinib, osimertinib
BRCA-Mutated Breast CarcinomaHER2-negative Breast Cancer

Neoadjuvant Treatment of gBRCA-Mutated HER2-Negative Breast Cancer With HRS-1167 and Famitinib ± Camrelizumab

RECRUITING
NCT06516289Phase PHASE2Fudan UniversityStarted 2024-09-30
HRS-1167FamitinibCamrelizumab
Healthy

A Relative Bioavailability and Food Effect Study of TYRA-300-B01 Capsule and Tablet Formulations in Healthy Adult Participants

ACTIVE NOT RECRUITING
NCT06006702Phase PHASE1Tyra Biosciences, IncStarted 2023-10-16
TYRA-300-B01